Mercer Global Advisors Inc Geron Corp Transaction History

Mercer Global Advisors Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 08, 2023	SELL	$2.03 - $2.42 $101,499 - $121,000	-50,000 Reduced 64.3%	27,757 $67,000
Q3 2022 Nov 15, 2022	SELL	$1.67 - $2.94 $79,934 - $140,723	-47,865 Reduced 38.1%	77,757 $182,000
Q1 2022 May 10, 2022	BUY	$0.99 - $1.6 $69,300 - $112,000	70,000 Added 125.85%	125,622 $171,000
Q4 2021 Feb 04, 2022	BUY	$1.22 - $1.72 $14,038 - $19,792	11,507 Added 26.08%	55,622 $68,000
Q2 2021 Aug 10, 2021	BUY	$1.25 - $1.83 $23,116 - $33,842	18,493 Added 72.18%	44,115 $62,000
Q1 2021 May 11, 2021	BUY	$1.52 - $2.1 $38,945 - $53,806	25,622 New	25,622 $40,000
Q4 2019 Feb 13, 2020	SELL	$1.27 - $1.54 $32,948 - $39,953	-25,944 Closed	0 $0
Q3 2019 Nov 12, 2019	BUY	$1.15 - $1.59 $29,835 - $41,250	25,944 New	25,944 $34,000

259

450M

1.91M

897K

Ticker GERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 377,819,008
Market Cap $1.59B
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...

Get notified when there are updates to the investment portfolio of Mercer Global Advisors Inc , based on Form 13F filings with the SEC.

Stay updated on Mercer Global Advisors Inc with notifications on news.